From: Participatory medicine: a driving force for revolutionizing healthcare
Systems medicine | Healthcare outcome |
---|---|
Provides fundamental insights into dynamic disease-perturbed networks in model organisms | Enables mechanistic insights, diagnosis, therapy and prevention for the individual patient |
Pioneers family genome sequencing, identifying disease genes inexpensively and effectively | Identifies disease, wellness and drug-intolerant gene products. Identifies individuals who have any one or more of 300 actionable gene variants |
Transforms blood into a window to distinguish health from disease | Disease diagnostics, assesses drug toxicity and wellness; examples include lung cancer, post-traumatic stress disorder (PTSD), liver toxicity and hepatitis |
Stratifies diseases into their distinct subtypes | For selecting specific and effective drugs for each subtype |
Stratifies patients - drug adverse reactions, modifier genes to disease mechanisms, for example early and late onset of Huntington’s disease, variant genes that increase mercury susceptibility in children | Stratifies patients for appropriate treatments |
Permits a multi-organ approach to the study of disease | Unravels the complexity of the individual patient’s disease and how a single disease affects multiple organs |
Enables new computational approaches to pioneering drug reuse and drug target discovery | Re-engineers disease-perturbed networks to normalcy with drugs and repurpose drugs. Faster and cheaper to develop drugs that prevent networks from becoming disease-perturbed |
Focuses on wellness | Wellness is a driver for P4 medicine of the future |
Creates large-scale, multiparameter, Framingham-like clinical trials to permit the longitudinal analyses of disease or wellness states | These studies will provide insights into early disease mechanisms and will provide new approaches to diagnosis and therapy |